Structure and mechanism of action of tau aggregation inhibitors

Katryna Cisek, Grace L. Cooper, Carol J. Huseby, Jeff Kuret

Research output: Contribution to journalArticlepeer-review

49 Scopus citations

Abstract

Since the discovery of phenothiazines as tau protein aggregation inhibitors, many additional small molecule inhibitors of diverse chemotype have been discovered and characterized in biological model systems. Although direct inhibition of tau aggregation has shown promise as a potential treatment strategy for depressing neurofibrillary lesion formation in Alzheimer’s disease, the mechanism of action of these compounds has been unclear. However, recent studies have found that tau aggregation antagonists exert their effects through both covalent and non-covalent means, and have identified associated potency and selectivity driving features. Here we review small-molecule tau aggregation inhibitors with a focus on compound structure and inhibitory mechanism. The elucidation of inhibitory mechanism has implications for maximizing on-target efficacy while minimizing off-target side effects.

Original languageEnglish (US)
Pages (from-to)918-927
Number of pages10
JournalCurrent Alzheimer research
Volume11
Issue number10
DOIs
StatePublished - Dec 1 2014
Externally publishedYes

Keywords

  • Aggregation
  • Alzheimer’s disease
  • Neurofibrillary tangle
  • Paired helical filaments
  • Tau

ASJC Scopus subject areas

  • Neurology
  • Clinical Neurology

Fingerprint

Dive into the research topics of 'Structure and mechanism of action of tau aggregation inhibitors'. Together they form a unique fingerprint.

Cite this